Sugi Predict

Sugi Predict / Compounds / SCHEMBL16636871

SCHEMBL16636871

SCHEMBL16636871

Clc1ccccc1-c1c[nH]c2ncnc(Cl)c12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 12/20 0.61
▸ CHEK1 O14757 1/20 0.51
▸ BRAF P15056 1/20 0.49
▸ TNNI3K Q59H18 1/20 0.49
▸ JAK2 O60674 2/20 0.44
▸ JAK3 P52333 1/20 0.44
▸ AKT1 P31749 1/20 0.43
▸ STK4 Q13043 4/20 0.42
▸ STK3 Q13188 4/20 0.42
▸ CCNE2 O96020 1/20 0.40
▸ CCNE1 P24864 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ PRKD3 O94806 1/20 0.40
▸ MAP4K4 O95819 1/20 0.40
▸ PAK4 O96013 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ PRKACA P17612 1/20 0.40
▸ LTK P29376 1/20 0.40
▸ MAP2K2 P36507 1/20 0.40
▸ MAPK8 P45983 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30372928 0.84 LRRK2 (0.59) LRRK2CHEK1JAK2JAK3STK4
SCHEMBL3226104 0.82 LRRK2 (0.61) LRRK2CHEK1JAK2JAK3STK4
SCHEMBL29378308 0.82 LRRK2 (0.61) LRRK2CHEK1JAK2JAK3STK4
SCHEMBL31301669 0.77 LRRK2 (1.00) LRRK2STK4STK3
SCHEMBL15400752 0.77 LRRK2 (1.00) LRRK2STK4STK3
SCHEMBL31329069 0.75 CHEK1 (0.66) LRRK2CHEK1BRAFTNNI3KJAK3
SCHEMBL1598149 0.75 CHEK1 (0.66) LRRK2CHEK1BRAFTNNI3KJAK3
SCHEMBL6422496 0.74 STK3 (0.61) LRRK2CHEK1JAK2JAK3STK4
SCHEMBL19533502 0.74 LRRK2 (0.52) LRRK2CHEK1JAK2JAK3STK4
SCHEMBL7060408 0.73 STK3 (0.56) LRRK2CHEK1BRAFTNNI3KJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20220242875-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2022-08-04 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS LRRK2 53/4885CHEK1 833/4885BRAF 23/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS LRRK2 63/4885CHEK1 165/4885BRAF 15/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 63/4885CHEK1 165/4885BRAF 15/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 40/4885CHEK1 443/4885BRAF 19/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 40/4885CHEK1 443/4885BRAF 19/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 40/4885CHEK1 443/4885BRAF 19/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 40/4885CHEK1 443/4885BRAF 19/4885
US-20220242875-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 40/4885CHEK1 443/4885BRAF 19/4885
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS LRRK2 2016/4885CHEK1 41/4885BRAF 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.